寡转移性疾病的影像学策略与技术挑战:欧洲癌症研究与治疗组织影像学组的推荐
本文由欧洲癌症研究与治疗组织影像学组提出,讨论寡转移性疾病(OMD)患者标准影像(CT/MRI上的RECIST测量及骨闪烁显像)与先进影像(功能、代谢及放射性核素靶向)在识别和随访中的应用,强调影像需按肿瘤类型、转移部位及既往治疗时间点量身定制,并呼吁合理使用全身影像方法。
要点
- OMD的影像需求随肿瘤类型、转移部位及与既往治疗的时间关系而变化。
- 标准影像采用CT/MRI上的RECIST测量及骨闪烁显像,先进影像包括功能、代谢及放射性核素靶向方法。
- 18F-FDG-PET/CT、弥散加权MRI、18F-胆碱-PET/CT和68Ga-PSMA-PET/CT等全身方法的选择需依据临床风险评估进行合理化。
核心结论
- 在疾病周期各节点(诊断、疗效评估和随访),影像必须针对临床问题及既往治疗背景进行定制,优化的标准化影像方法将使OMD试验能够记录疾病进展模式和治疗结局。
研究设计与样本
- 欧洲癌症研究与治疗组织影像学组发布的推荐文件,基于证据讨论并提出建议;提及Oligocare试验为正在建立的前瞻性、大规模观察性篮式研究,旨在收集接受放疗的OMD患者的结局数据。
诊断标准与关键数值
- 标准影像采用CT和MRI上的RECIST测量及骨闪烁显像。
- 先进影像包括功能、代谢及放射性核素靶向方法。
- OMD的影像需求随肿瘤类型、转移部位及与既往治疗的时间关系而变化。
临床应用与阅片要点
- 在诊断、疗效评估和随访各节点,影像需针对临床问题及既往治疗背景进行定制。
- 18F-FDG-PET/CT、弥散加权MRI、18F-胆碱-PET/CT和68Ga-PSMA-PET/CT等全身方法的选择需依据临床风险评估进行合理化。
- 纳入欧洲癌症研究与治疗组织影像平台等数据库的质量保证和质量控制影像数据,可建立高质量影像仓库供未来研究使用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Patients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD. Imaging requirements for recognising OMD vary with tumour type, metastatic location, and timing of measurement in relation to previous treatment. At each point in the disease cycle (diagnosis, response assessment and follow-up), imaging must be tailored to the clinical question and the context of prior treatment. The differential use of whole-body approaches such as 18F-FDG-positron emission tomography (PET)/CT, diffusion-weighted MRI, 18F-Choline-PET/CT and 68Ga-prostate specific membrane antigen-PET/CT require rationalisation depending on clinical risk assessment. Optimal standardised imaging approaches will enable OMD trials to document patterns of disease progression and outcomes of treatment. Quality assured and quality controlled imaging data included in databases such as the European Organisation for Research and Treatment of Cancer Imaging platform for the Oligocare trial (a prospective, large-scale observational basket study being set up to collect outcome data from patients with OMD treated with radiation therapy) will establish a large and high-quality imaging warehouse for future research.
引用
- deSouza NM, Liu Y, Chiti A, et al. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2018. PMID: 29331524. doi:10.1016/j.ejca.2017.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。